HC Wainwright Issues Negative Estimate for HRMY Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities researchers at HC Wainwright lowered their Q1 2026 earnings per share (EPS) estimates for shares of Harmony Biosciences in a research note issued on Wednesday, February 25th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $0.76 for the quarter, down from their previous forecast of $0.86. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q2 2026 earnings at $0.92 EPS, Q3 2026 earnings at $1.09 EPS, Q4 2026 earnings at $1.31 EPS and FY2030 earnings at $7.07 EPS.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.38 earnings per share for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.46). The business had revenue of $243.78 million for the quarter, compared to analyst estimates of $240.04 million. Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The company’s revenue was up 21.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.85 EPS.

HRMY has been the subject of several other research reports. UBS Group reduced their price objective on shares of Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating for the company in a research note on Wednesday. Bank of America reduced their price target on shares of Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating for the company in a research report on Wednesday. Needham & Company LLC decreased their price target on Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a research note on Wednesday. Wall Street Zen raised Harmony Biosciences from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. Finally, Truist Financial cut Harmony Biosciences from a “buy” rating to a “hold” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $42.67.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY opened at $29.05 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.72 and a current ratio of 3.60. Harmony Biosciences has a one year low of $25.52 and a one year high of $40.87. The firm has a market capitalization of $1.68 billion, a P/E ratio of 10.72, a PEG ratio of 0.39 and a beta of 0.84. The company’s fifty day moving average is $36.19 and its two-hundred day moving average is $34.12.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, CEO Jeffrey M. Dayno sold 25,933 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $40.11, for a total transaction of $1,040,172.63. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Sandip Kapadia sold 20,961 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $35.92, for a total value of $752,919.12. The SEC filing for this sale provides additional information. Insiders have sold a total of 50,640 shares of company stock valued at $1,932,256 over the last 90 days. Insiders own 23.60% of the company’s stock.

Institutional Trading of Harmony Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its stake in Harmony Biosciences by 589.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after purchasing an additional 643 shares during the last quarter. Leonteq Securities AG purchased a new stake in shares of Harmony Biosciences during the fourth quarter worth about $30,000. Allworth Financial LP grew its holdings in shares of Harmony Biosciences by 286.7% during the fourth quarter. Allworth Financial LP now owns 812 shares of the company’s stock worth $30,000 after buying an additional 602 shares in the last quarter. Parkside Financial Bank & Trust raised its position in shares of Harmony Biosciences by 4,185.2% in the second quarter. Parkside Financial Bank & Trust now owns 1,157 shares of the company’s stock valued at $37,000 after buying an additional 1,130 shares during the last quarter. Finally, Clearstead Advisors LLC lifted its stake in shares of Harmony Biosciences by 145.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock valued at $44,000 after buying an additional 699 shares during the period. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Key Headlines Impacting Harmony Biosciences

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and kept a $55 price target, signaling strong upside from current levels and providing bullish support for long investors. HC Wainwright Reaffirms Buy
• Positive Sentiment: Needham & Company maintained a “buy” rating and a $44 target after a small cut, which keeps another buy-side endorsement in the tape and supports demand from growth-oriented investors. Needham Buy Rating
• Neutral Sentiment: UBS trimmed its price target from $46 to $36 and set a “neutral” rating — a meaningful reduction in upside but not a sell call, which may temper enthusiasm without forcing broad liquidation. UBS Lowers PT to $36
• Neutral Sentiment: An analyst-aggregate report shows an average rating of “Moderate Buy,” indicating mixed but overall constructive analyst sentiment that can limit downside from negative headlines. Analyst Average Rating
• Negative Sentiment: Truist Securities downgraded HRMY to “Hold” after developments in a patent trial, flagging increased legal/competitive risk that could pressure future revenue or margins if adverse outcomes persist. Truist Downgrade After Patent Trial
• Negative Sentiment: Bank of America cut its price target to $28 and moved to an “underperform” rating, which is explicitly bearish and adds selling pressure from institutional accounts that follow BofA coverage. BofA Lowers PT to $28

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.